State of Alaska Department of Revenue Trims Holdings in Integra LifeSciences Holdings Corporation $IART

State of Alaska Department of Revenue trimmed its holdings in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 72.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 38,205 shares of the life sciences company’s stock after selling 100,071 shares during the quarter. State of Alaska Department of Revenue’s holdings in Integra LifeSciences were worth $547,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in IART. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Integra LifeSciences by 5.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,441 shares of the life sciences company’s stock valued at $889,000 after buying an additional 1,975 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in shares of Integra LifeSciences during the first quarter valued at approximately $277,000. Goldman Sachs Group Inc. boosted its holdings in shares of Integra LifeSciences by 2.2% in the first quarter. Goldman Sachs Group Inc. now owns 1,660,511 shares of the life sciences company’s stock valued at $36,515,000 after purchasing an additional 35,790 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Integra LifeSciences by 23.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 244,335 shares of the life sciences company’s stock worth $5,373,000 after purchasing an additional 45,693 shares in the last quarter. Finally, Strs Ohio bought a new position in Integra LifeSciences in the first quarter worth approximately $400,000. 84.78% of the stock is currently owned by institutional investors.

Insider Transactions at Integra LifeSciences

In other Integra LifeSciences news, Director Jeffrey A. Graves purchased 9,000 shares of Integra LifeSciences stock in a transaction dated Wednesday, November 5th. The shares were acquired at an average cost of $11.35 per share, with a total value of $102,150.00. Following the completion of the transaction, the director owned 41,086 shares in the company, valued at approximately $466,326.10. This trade represents a 28.05% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 3.54% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Integra LifeSciences in a report on Monday, December 29th. Truist Financial restated a “hold” rating and issued a $13.00 price objective (down from $15.00) on shares of Integra LifeSciences in a report on Monday, November 3rd. Citigroup dropped their target price on shares of Integra LifeSciences from $12.00 to $11.00 and set a “sell” rating on the stock in a report on Friday, October 31st. JPMorgan Chase & Co. boosted their price target on shares of Integra LifeSciences from $12.00 to $13.00 and gave the company an “underweight” rating in a report on Friday, October 31st. Finally, Wall Street Zen raised shares of Integra LifeSciences from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Reduce” and an average price target of $15.00.

Integra LifeSciences Stock Performance

Shares of Integra LifeSciences stock opened at $12.01 on Wednesday. The company has a market capitalization of $935.46 million, a PE ratio of -1.86 and a beta of 1.02. The company has a 50-day simple moving average of $12.73 and a two-hundred day simple moving average of $13.43. Integra LifeSciences Holdings Corporation has a one year low of $10.87 and a one year high of $27.13. The company has a debt-to-equity ratio of 1.73, a quick ratio of 1.80 and a current ratio of 3.14.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings results on Thursday, October 30th. The life sciences company reported $0.54 earnings per share for the quarter, beating analysts’ consensus estimates of $0.43 by $0.11. The business had revenue of $402.06 million for the quarter, compared to analysts’ expectations of $414.31 million. Integra LifeSciences had a negative net margin of 30.15% and a positive return on equity of 14.06%. The company’s revenue was up 5.6% compared to the same quarter last year. During the same period last year, the business earned $0.41 EPS. Integra LifeSciences has set its Q4 2025 guidance at 0.790-0.840 EPS and its FY 2025 guidance at 2.190-2.240 EPS. Research analysts expect that Integra LifeSciences Holdings Corporation will post 2.45 EPS for the current fiscal year.

Integra LifeSciences Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.